Apellis Pharmaceuticals P/E Ratio

Apellis Pharmaceuticals's p/e ratio stands at 38.71. That is above the Healthcare sector average of 26.85. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Apellis Pharmaceuticals sits higher the Healthcare benchmark (26.85) with a P/E ratio of 38.71. That is roughly 44.2% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 38.71 is attractive depends on Apellis Pharmaceuticals's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Apellis Pharmaceuticals's P/E ratio evolved across reporting periods, while the comparison chart places APLS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Apellis Pharmaceuticals's reading of 38.71 (sector avg 26.85) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.